A Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations

About this Study

The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes and also to see if tumor genetic testing would be helpful at guiding treatment in patients .

Sponsor Protocol ID:A071401
IRB Number:2016-0059
Actively Enrolling
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion CriteriaThis study will be available to all eligible patients, regardless of race, gender, or ethnic origin.

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Takila Keys
Phone Number: 601-815-9479
Email: tkeys@umc.edu
Principal Investigator:Long, Robert C, M.D.
How to participate in our Clinical Trials